While metastatic and primary tumor cells of head and neck cancers share similar mutations, recurrent disease is associated with unique gene alterations that could be vulnerable to a cancer drug, new research has found. Researchers from the University of Pittsburgh Cancer Institute (UPCI) and Yale University School of Medicine will share their findings during a mini-symposium Sunday at the American Association for Cancer Research Annual Meeting 2014. About ...Sunday 6 April 2014
New Research Finds Recurrent Head and Neck Tumors Have Gene Mutations That Could be Vulnerable to Cancer Drug
While metastatic and primary tumor cells of head and neck cancers share similar mutations, recurrent disease is associated with unique gene alterations that could be vulnerable to a cancer drug, new research has found. Researchers from the University of Pittsburgh Cancer Institute (UPCI) and Yale University School of Medicine will share their findings during a mini-symposium Sunday at the American Association for Cancer Research Annual Meeting 2014. About ...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment